Mycoplasma hominis and Mycoplasma genitalium are not the same organism. They are two distinct bacterial species that belong to the same genus (Mycoplasma), which is why their names are easy to confuse. But they differ in important ways: where they tend to live, what symptoms they cause, how they’re detected, and how they’re treated.
Two Different Bacteria With Similar Names
Both M. hominis and M. genitalium are tiny bacteria that lack a cell wall, which already sets them apart from most other bacteria. They’re both sexually transmitted and can colonize the urogenital tract. That’s roughly where the similarities end.
M. hominis is relatively common in the genital tract and can sometimes be found in people with no symptoms at all. It grows fairly well in laboratory culture, making it easier to detect through traditional methods. It’s most often associated with bacterial vaginosis, postpartum fever, and certain infections after gynecological surgery. In many cases, M. hominis lives in the genital tract without causing obvious disease, which makes it harder to pin down as the sole cause of symptoms.
M. genitalium (sometimes shortened to Mgen) is a recognized sexually transmitted pathogen. It can infect the cervix, urethra, or rectum. Most people with Mgen have no symptoms, but when symptoms do appear they typically include vaginal discharge, discharge from the penis, or a burning sensation when urinating. Left untreated in women, Mgen can lead to pelvic inflammatory disease (PID), which carries serious consequences: scarring of the fallopian tubes, ectopic pregnancy, infertility, and chronic pelvic pain. During pregnancy, Mgen may be linked to preterm delivery or pregnancy loss. Whether men develop long-term complications from Mgen is still unknown.
Why Testing Differs for Each
One of the biggest practical differences between these two bacteria is how they’re detected. M. hominis can be grown in standard laboratory culture media, so doctors have historically been able to identify it with conventional methods. M. genitalium is the opposite: it grows extremely slowly in the lab and has very demanding culture requirements, making traditional culture essentially useless for diagnosis.
Because of this, molecular tests (called nucleic acid amplification tests, or NAATs) are the recommended way to detect M. genitalium. Several FDA-cleared commercial assays now exist for Mgen, including tests from Hologic, Roche, and Abbott that can identify it alongside other STIs like chlamydia and gonorrhea. Some newer multiplex panels test for both M. genitalium and M. hominis at the same time, which is one reason patients sometimes see both names on the same lab report and wonder if they’re the same thing. They aren’t, and a positive result for one does not mean you have the other.
Treatment Is Not Interchangeable
Because neither bacterium has a cell wall, common antibiotics like penicillin and cephalosporins don’t work against either one. But the specific antibiotics that do work, and the challenges involved, are quite different for each.
M. hominis generally responds to certain antibiotics and is considered more straightforward to treat, though it is naturally resistant to macrolide antibiotics like azithromycin.
M. genitalium is a much trickier treatment challenge. Macrolide resistance in Mgen is widespread, with molecular markers for resistance found in 44% to 90% of samples in the U.S., Canada, Western Europe, and Australia. Treating a macrolide-susceptible Mgen infection with a single dose of azithromycin can actually create resistance in 10% to 12% of cases. For this reason, the CDC recommends against using a one-gram dose of azithromycin alone. Instead, a two-stage treatment approach is preferred, ideally guided by resistance testing that checks whether the specific strain will respond to a given antibiotic. When resistance-guided therapy is available, cure rates exceed 90%.
Resistance to a second class of antibiotics, fluoroquinolones, is less common in Mgen (0% to 15% in U.S. studies), but when it does occur it often appears alongside macrolide resistance, making those cases especially difficult to treat. The catch is that commercial resistance testing for Mgen is not yet widely available in the United States, so clinicians sometimes have to make treatment decisions without knowing exactly which drugs will work.
Which One Should You Be More Concerned About?
If you’ve tested positive for M. hominis, the clinical picture depends on context. In many people, especially those without symptoms, M. hominis colonization doesn’t necessarily require treatment. It becomes more relevant when it’s linked to a specific condition like bacterial vaginosis or a post-surgical infection.
M. genitalium, on the other hand, is treated as a true STI with a clearer path to complications. The risk of PID and its downstream effects on fertility make untreated Mgen a real concern for women. Because most Mgen infections produce no symptoms, someone can carry and transmit it without knowing. This is one reason some experts have pushed for broader screening, although routine testing for Mgen is not yet standard in the U.S.
If you’ve seen both names on a test panel, the key takeaway is simple: these are two separate infections with different risk profiles and different treatment plans. A positive result for one tells you nothing about the other, and managing them requires different clinical decisions.